Surface Oncology, Inc.

NasdaqCM:SURF Rapporto sulle azioni

Cap. di mercato: US$65.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology Gestione

Gestione criteri di controllo 3/4

Surface Oncology Il CEO è Rob Ross, nominato in Apr2021, e ha un mandato di 2.42 anni. la retribuzione annua totale è $ 1.92M, composta da 29.5% di stipendio e 70.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.14% delle azioni della società, per un valore di $ 89.02K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4.7 anni.

Informazioni chiave

Rob Ross

Amministratore delegato

US$1.9m

Compenso totale

Percentuale dello stipendio del CEO29.5%
Mandato del CEO2.4yrs
Proprietà del CEO0.1%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11
News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 23
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Jan 18

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Nov 11
Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Oct 24

Surface Oncology: A Diverse, But Early Pipeline

Jul 13

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Jun 07
Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology EPS beats by $0.04, beats on revenue

May 05

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15
Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08
What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rob Ross rispetto agli utili di Surface Oncology?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$568k

-US$64m

Sep 30 2022n/an/a

-US$66m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$5mUS$506k

-US$78m

Sep 30 2021n/an/a

US$13m

Jun 30 2021n/an/a

US$17m

Mar 31 2021n/an/a

US$21m

Dec 31 2020US$1mUS$435k

US$59m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$810kUS$400k

-US$55m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$44m

Mar 31 2019n/an/a

-US$35m

Dec 31 2018US$880kUS$361k

-US$7m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$467kUS$329k

-US$45m

Compensazione vs Mercato: La retribuzione totale di Rob ($USD 1.92M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 646.00K ).

Compensazione vs guadagni: La retribuzione di Rob è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Rob Ross (49 yo)

2.4yrs

Mandato

US$1,924,455

Compensazione

Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Robert Ross
President2.4yrsUS$1.92m0.14%
$ 89.0k
Alison O'Neill
Chief Medical Officer3.6yrsUS$1.06mNessun dato
Jessica Fees
CFO & Treasurer4.8yrsNessun dato0.17%
$ 109.1k
Chandra Adams
Deputy General Counsel & Secretaryless than a yearNessun dato0.051%
$ 33.1k
Lisa McGrath
Chief People Officerno dataNessun datoNessun dato
Shannon Devens
Senior Vice President of Development Operations1.8yrsNessun datoNessun dato

2.4yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di SURF è considerato esperto (durata media dell'incarico 2.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Robert Ross
President2.4yrsUS$1.92m0.14%
$ 89.0k
Charles Sigal
Independent Member of Scientific Advisory Board & Director5.6yrsUS$80.57k0.075%
$ 48.6k
David Grayzel
Independent Director9.4yrsUS$84.57k0%
$ 0
J. Goater
Director5.6yrsUS$72.57k0.21%
$ 138.3k
Alexander Rudensky
Member of Scientific Advisory Board4.7yrsNessun datoNessun dato
Armen Shanafelt
Independent Director8.8yrsUS$89.07k0%
$ 0
Laurie Stelzer
Independent Director5.6yrsUS$92.57k0%
$ 0
F. Hodi
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Denice Torres
Independent Chairman & Lead Independent Director2.2yrsUS$151.82k0%
$ 0
Christopher Hunter
Member of Scientific Advisory Board4.7yrsNessun datoNessun dato
Carla Rothlin
Member of Scientific Advisory Board4.7yrsNessun datoNessun dato
Arlene Sharpe
Member of Scientific Advisory Board4.7yrsNessun datoNessun dato

4.7yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SURF sono considerati esperti (durata media dell'incarico 4.7 anni).